

Review > Neurourol Urodyn. 2022 Feb 3. doi: 10.1002/nau.24878. Online ahead of print.

## Pad test for urinary incontinence diagnosis in adults: Systematic review of diagnostic test accuracy

Camilla Medeiros Araujo <sup>1</sup>, Nívea Rosa de Moraes <sup>1</sup>, Cinara Sacomori <sup>2</sup>, Diego de Sousa Dantas <sup>1</sup>

Affiliations + expand

PMID: 35114027 DOI: 10.1002/nau.24878

### Abstract

**Introduction:** The pad test is an assessment tool for urinary incontinence (UI) severity classification and therapeutic response monitoring. However, the reliability and reproducibility of this test have been questioned.

**Objectives:** To summarize the evidence regarding the accuracy measures and reproducibility of different pad test protocols for assessing UI.

1

2 **Accepted version, published at Neurourol Urodyn. 2022;1–13.**

3

4 **Pad test for urinary incontinence diagnosis in adults:**

5 **Systematic review of diagnostic test accuracy**

6

7 Camilla Medeiros Araujo<sup>1</sup> | Nívea Rosa de Moraes<sup>1</sup> | Cinara Sacomori<sup>2</sup> |

8 Diego de Sousa Dantas<sup>1</sup>

9

10 Physiotherapy Department, Universidade Federal de Pernambuco (UFPE), Recife,  
11 Brazil

12 Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

13

### 14 Abstract

15 **Introduction:** The pad test is an assessment tool for urinary incontinence (UI) severity  
16 classification and therapeutic response monitoring. However, the reliability and  
17 reproducibility of this test have been questioned. **Objectives:** To summarize the evidence

FULL TEXT LINKS



ACTIONS



SHARE



PAGE NAVIGATION

< Title & authors

18 regarding the accuracy measures and reproducibility of different pad test protocols for  
19 assessing UI more objectively. **Methods:** A systematic review of the diagnostic accuracy  
20 of this tool was performed (CRD42020219392). **Eligibility criteria:** Studies reporting data  
21 on the accuracy measures and reproducibility of the pad test when used for detecting UI  
22 in adult men and women. **Data Sources:** MEDLINE, Science Direct, Cochrane Database,  
23 Web of Science, LILACS, and Pedro databases. **Data extraction and synthesis:** Two  
24 reviewers independently screened the articles, extracted the data and evaluated the risk  
25 of bias using the QUADAS-2 tool. **Results:** From 1048 studies, 18 studies were included.  
26 Eight of these reported accuracy data, and 12 reported reproducibility properties. A total  
27 of 1070 individuals were analysed, whose mean age ranged from 20 to 90 years. The  
28 accuracy of the long-duration protocols was generally moderate to high (sensitivity, 60%–  
29 93%; specificity, 60%–84%). The 1-hour protocols obtained higher accuracy values than  
30 the long-duration protocols. The overall reproducibility was moderate to high ( $\kappa \geq 0.66$ ).  
31 **Limitations:** The risk of bias among the studies was high and, due to different cut-off  
32 points adopted by studies, the bivariate model was not satisfied to perform a meta-  
33 analysis. **Discussion:** The 1-hour pad test was more accurate but less reproducible when  
34 compared to the long-duration tests. Pad test results should be used with caution in  
35 clinical practice.

36

37 **Keywords:** Urinary incontinence; Severity of illness index; Data accuracy; Reproducibility  
38 of results; Measures of association, exposure, risk or outcome.

39

## 40Introduction

41 Urinary incontinence (UI) is a clinical condition that may affect men and women  
42from children to older adults<sup>1</sup>. Diagnosis of UI severity is made clinically and with the  
43urodynamic test as the gold standard in evaluating lower urinary tract function <sup>2</sup>. However,  
44the limiting factors of the urodynamic test include its high cost and invasiveness <sup>3</sup>.  
45Practising clinicians may also use several validated questionnaires, voiding diaries, and  
46the pad test<sup>4</sup> to identify UI and associated symptoms.

47 The pad test is useful in clinical and scientific practice as an additional tool in the  
48diagnosis and classification of UI severity, and as such indirectly influences the choice of  
49treatment and therapeutic response monitoring<sup>4,5</sup>. It is recommended by the International  
50Continence Society (ICS) with grade C level 3 evidence<sup>4,5</sup> standing out for being non-  
51invasive, relatively easy, inexpensive, and for presenting a good correlation with UI  
52assessment questionnaires <sup>6</sup>.

53 Proposed by James et al. in 1971<sup>7</sup>, the pad test was intended to assess UI by  
54weighing pads. Ten years later, it was associated with stimulation exercises by Sutherst  
55et al<sup>8</sup>. The more widespread protocols are divided into four types: the 20-min <sup>9</sup>,  
56standardized 1-hour <sup>10</sup>, 24-hour <sup>11</sup>, and 48-hour protocols <sup>12</sup>. However, the reliability and  
57reproducibility of this test have been questioned, as the short duration tests are restricted  
58to experimental situations on urethral insufficiency, offering a limited impression of daily  
59urinary loss situations <sup>13</sup>. The longer duration tests (24-, 48-, and 72-hour) seem to be  
60more reproducible, but with lower patient compliance <sup>14</sup>. In the long duration tests,  
61patients are exposed to daily life situations that might increase intra-abdominal pressure

62or provoke urgency. Meanwhile, in the short-duration tests patients are exposed to a  
63standardized set of activities <sup>14</sup>.

64 In clinical practice, the decision-making process to choose any of these tools  
65should be based on parameters of test accuracy related to a gold standard. These  
66parameters are expressed by sensitivity, specificity, positive and negative predictive  
67values, and positive and negative likelihood ratios. Reproducibility is another relevant  
68parameter to estimate the concordance of measures of test and recommend its use<sup>15</sup>.

69 The measurement properties of the pad test have been investigated, producing  
70conflicting results. Studies show a low correlation between the urodynamic examination  
71results and the 24-hour pad test results <sup>16</sup>. The results of comparing the 1-hour and 24-  
72hour protocols showed a good correlation (0.86) but poor agreement (Cohen's kappa  
73coefficient  $\kappa = 0.25$ ) in UI severity classification <sup>13</sup>.

74 In this context, this review aims to summarize the evidence of the accuracy  
75measures and reproducibility of different pad test protocols in detecting more objectively  
76UI in men and women, as well as to investigate the quality of this evidence.

## 77**Methods**

78 This systematic review was registered in the Prospective Register of Systematic  
79Reviews (PROSPERO) under number CRD42020219392. Preferred Reporting Items for  
80a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies<sup>17</sup>, and the  
81Cochrane Handbook for Systematic Review of Diagnostic Test Accuracy<sup>18</sup> were followed.

## 82**Eligibility Criteria**

83 Any cross-sectional or prospective studies reporting data on the accuracy  
84measures and reproducibility properties of any pad test protocol for objectively detecting  
85UI or measuring loss of urine in adult women and men ( $\geq 18$  years) were eligible for this  
86systematic review. The studies included cover a period from 1971, the publication year  
87of the first version of the pad test <sup>7</sup>, to the search date (December 08, 2021). There was  
88no language limitation.

89 Narrative and systematic reviews, letters to the editor, editorials, case studies, and  
90case series, as well as studies that did not report data on accuracy measures, or that  
91presented insufficient data to calculate these values, were excluded.

## 92**Diagnostic test**

93 We included articles that reported the clinimetric properties of pad tests of 20  
94minutes, 1h, 24h, and 48 hours, as well as studies that dealt with pad test reproducibility  
95measures. Urodynamic<sup>2</sup> and/or videourodynamic<sup>19</sup> studies were considered the gold  
96standard in diagnosing UI.

## 97**Search for articles and data collection**

98 One of the researchers searched for articles using MEDLINE via the EBSCO,  
99Science Direct, Cochrane Database, Web of Science, PubMed, and Pedro databases.  
100The following descriptors were used: pad test, accuracy, sensitivity, specificity,  
101reproducibility of results [MeSH], reliability, and urinary incontinence, with the Boolean  
102operators AND/OR. The search strategy (supplementary material) was differentiated for  
103each database and involved combining the descriptors mentioned above. In addition,  
104relevant articles identified from the references were included.

105 Two reviewers independently screened and analysed the eligibility of the articles.  
106 After excluding duplicate entries, the studies were screened by reading the titles and  
107 abstracts, and were assessed for eligibility criteria by reading the full text. A third reviewer  
108 resolved disagreements for the final consensus.

109 The researcher extracted the data based on an electronic questionnaire developed  
110 for the study containing the following: authors, year of publication, study design, sample  
111 size, participants' sex, mean age, UI type, type of pad test performed, true and false  
112 negatives and positives, sensitivity and specificity values with confidence intervals,  
113 statistical test, and interval between the performance of the tests in days. The data were  
114 then registered in tables.

#### 115 **Outcome measures**

116 The primary outcomes were the accuracy values (sensitivity and specificity), and  
117 the secondary outcomes were the reproducibility measures (test-retest measures,  
118 intraclass correlation coefficient, agreement, and standard deviation).

#### 119 **Assessment of the risk of bias and applicability**

120 The risk of bias (RoB) of studies investigating diagnostic accuracy was verified  
121 using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool<sup>20</sup>, which  
122 comprises four domains: participant selection, index test, standardised reference test,  
123 and participant flow. Each domain was evaluated as to the ROB and also the clinical  
124 applicability concerning the participants and tests evaluated.

125 The Guideline for Reporting Reliability and Agreement Studies (GRRAS) was used  
126to evaluate the RoB of the reproducibility measures. The GRRAS addresses 15 items  
127related to the title and abstract, introduction, methodology, presentation of results,  
128discussion, and auxiliary material <sup>21</sup>. A score was developed using the number of  
129accomplished items divided by the total number of applicable items by each study. Higher  
130scores demonstrate that the studies report more reliable results.

### 131**Data analysis**

132 The outcomes were analysed using Review Manager (RevMan) (version 5.4.1;  
133Cochrane Collaboration, 2020). Non-explicit sensitivity and specificity values were  
134automatically calculated by RevMan from the number of true-positive, true-negative,  
135false-positive, and false-negative cases. Thus, we recreated the 2×2 contingency tables  
136and calculated sensitivity, specificity, and positive and negative predictive values, as well  
137as the 95% confidence intervals (CIs).

138 The inter-rater agreement in the article selection phase was analysed using the  
139calculated  $\kappa$  from the observed and random agreements, which was interpreted as  
140follows: 0 to 0.20 (no agreement), 0.21 to 0.39 (minimal), 0.49 to 0.59 (weak), 0.60 to  
1410.79 (moderate), 0.80 to 0.90 (strong)and above 0.90 (near perfect) <sup>22</sup>.

### 142**Results**

#### 143**Selection of studies**

144 The process of study selection has been represented in a flow diagram (Figure 1).  
145 After the screening process, 18 studies were included in the qualitative synthesis, among  
146 which eight addressed accuracy measures, and 12 presented reproducibility measures.

147 The screening process showed moderate agreement between the evaluators ( $\kappa =$   
148 0.702).

### 149 **Characteristics of the included studies**

150 A total of 1070 individuals were included in the studies evaluating the accuracy of  
151 the pad test (Table 1), with 617 participants included in the studies that evaluated the  
152 reproducibility of the test (Table 2).

### 153 **Risk of bias**

154 The RoB and applicability are presented graphically in percentages and detailed  
155 by study (Figure 2).

156 The selection of participants was the primary source of bias in the included studies,  
157 as most studies, except that of Matharu et al.<sup>23</sup>, only included volunteers with  
158 incontinence complaints.

159 The studies also showed biases in interpreting the test results. In three studies<sup>24–</sup>  
160<sup>26</sup> it was not clearly described if the evaluator was blinded, i.e. whether the pad test was  
161 analysed without knowing the urodynamic test result. In another three studies<sup>27–29</sup>, the  
162 participants performed the pad test after knowing the urodynamic study result.

163 Regarding flow and timing Bias, the interval between tests was poorly described  
164 in the studies by Karantanis et al.<sup>24</sup> and Price and Noblett<sup>26</sup>. Data were not completely



165analysed in the study by Versi et al.<sup>27</sup> with only healthy and stress UI-diagnosed  
166volunteers included in the urodynamic study.

167 The studies generally showed good applicability of concepts concerning participant  
168selection, index testing, and reference testing. We highlight that only Timmermans et al.  
169<sup>25</sup> included men in their sample. Only the study by Matharu et al.<sup>23</sup> showed low  
170applicability because the researchers modified the 1-hour pad test protocol and excluded  
171the activity of climbing a flight of stairs, considering the participants' physical limitations.

172 None of the 12 included studies<sup>9,11,24,30-38</sup> on pad test reproducibility met the  
173criteria of all 15 items recommended by GRRAS (Table 3). The main inadequacies  
174regarding methodology were related to sample selection and calculation, the number of  
175raters and repeated measures, and whether the evaluations and interpretations occurred  
176independently. Regarding the description of the results, most did not present the  
177characteristics of the sample of raters and participants or included measures of statistical  
178uncertainty.

## 179**Summary of results**

180 The synthesis of the results is described by the type of pad test (Figure 3). A meta-  
181analysis of the studies was not possible because of differences in the cut-off point  
182between the long-duration studies, and the small number of short-duration studies which  
183also presented some methodological limitations. Some studies did not present the  
184sensitivity/specificity values<sup>23-25,39</sup>; therefore, they were calculated and presented in the  
185Forest Plot (Figure 3).

## 186**48-hour pad test**

187 Only the study by Versi et al.<sup>27</sup> analysed the accuracy properties of the 48-hour  
188 pad test among 105 participants. The cut-off point value for UI diagnosis at 15 g had a  
189 sensitivity of 92% (95% CI, 82%–97%) and specificity of 84% (95% CI, 68%–94%),  
190 compared to that of the urodynamic test.

191 Three studies<sup>27,33,37</sup> presented intra-examiner reproducibility analysis with  
192 coefficients ranging from 0.87 to 0.94.

### 193 **24-hour pad test**

194 Three studies<sup>23,24,26</sup> analysed the properties of the 24-hour pad test among a total  
195 of 504 participants. However, each study analysed a different cut-off point. When the 1-g  
196 cut-off point<sup>24</sup> was adopted, a sensitivity of 100% was estimated, but specificity could not  
197 be verified. For the 4-g cut-off point<sup>23</sup>, sensitivity of 63% (95% CI, 57%–69%) and  
198 specificity of 64% (95% CI: 49%–77%) were estimated. At the 8-g cut-off point<sup>26</sup> sensitivity  
199 and specificity were both 60% (95% CIs, 45%–74% and 15%–95%, respectively).

200 The reproducibility was analysed by seven studies<sup>11,27,31,33,34,37</sup>, calculating  
201 correlation coefficients between 0.66 and 0.9. Variabilities of 69.5–133.4 g was identified  
202 between consecutive pad tests, depending on the level of physical activity of the  
203 participant (95% CI, 80.4–186.5 g)<sup>31</sup>.

### 204 **1-hour pad test**

205 Four studies<sup>23,25,28,39</sup>, with a total of 719 participants, analysed the properties of the  
206 1-hour pad test. The cut-off point value utilized was 1 g, and the sensitivity and specificity  
207 values ranged 34%–95% and 60%–100%, respectively.

208 The reproducibility of the 1-hour pad test was evaluated by two studies<sup>32,38</sup> with a  
209 correlation coefficient of 0.96 between the two measurements<sup>32</sup>. In contrast, a mean  
210 difference of  $9.7 \pm 29.7$  g was identified by the Bland Altman analysis, with the second  
211 measurement varying from 66 g below to 46 g above the first test result <sup>38</sup>.

## 212 **20-min pad test**

213 Only two studies<sup>28,29</sup> with a total of 183 participants analysed the properties of the  
214 20-min pad test. The cut-off point value used was 1 g, and identified sensitivities between  
215 46% (95% CI, 36%–56%) and 71% (95% CI, 60%–81%). Specificity could not be  
216 estimated or reported in the studies because of participant selection bias.

217 Three studies<sup>9,30,36</sup> analysed the reproducibility and presented correlation values  
218 between pad test measurements ranging from 0.75 to 0.94. The method error was 30%  
219 in the study by Hahn and Fall<sup>9</sup>.

## 220 **Discussion**

221 This review summarized the data of the long- and short-duration pad tests  
222 accuracy and reproducibility in assessing UI and measure loss of urine in adults. Eighteen  
223 studies were identified, most of them involving women. The lack of studies and reference  
224 values for the male population draws attention because the pad test is recommended in  
225 assessing UI in men, having been adopted as the gold standard in the validation of  
226 instruments related to UI severity <sup>13</sup>; therefore there is still a need to study clinimetric  
227 properties of this test in men.

228 The cut-off values of the studies were similar only for the 20-min and 1-hour pad  
229tests, allowing comparison between these tests. The included studies used a 1g cut-off  
230in increase in pad weight to make a diagnosis according to the ICS standardization<sup>14</sup>.  
231However, the lower limit should be interpreted with prudence because weight gains of up  
232to 1.4 g or 4.4 g for 1 hour or 24-hr pad test, respectively, could be a result of sweating  
233or vaginal discharge. If the findings are inconclusive, clinicians may use oral  
234phenazopyridine to color the urine orange and distinguish the urine from other fluids<sup>14</sup>.

235 The identified accuracy measures were quite variable and associated with a strong  
236tendency to be overestimated due to research bias, mainly due to participant selection  
237bias<sup>20</sup>. The wide confidence intervals concerning the specificity measure point to the  
238imprecision of the test, probably due to the selection bias<sup>40</sup>. Several studies have used  
239the pad test as the diagnostic gold standard<sup>4,41</sup>; however, they present divergent accuracy  
240measures.

241 The accuracy of the 1-hour pad test was the most investigated; among the studies,  
242the one by Costantini et al.<sup>39</sup> stood out as having the lowest RoB, presenting a sensitivity  
243and specificity of 84% and 70%, respectively. The 20-minute pad test presented a  
244sensitivity of only 46% in studies with a lower RoB, and its specificity could not be  
245estimated due to selection bias.

246 Among the long-term protocols, the 24-hour pad test was the most investigated  
247and presented both sensitivity and specificity values of approximately 60% in studies with  
248a lower RoB. For the 1-g cut-off point<sup>24</sup>, a sensitivity of 100% was estimated, but the  
249studies involved only participants already diagnosed with UI, tending to overestimate the

250test's specificity<sup>20</sup>. Only one study evaluated the 48-hour pad test and had the most robust  
251results among the four tests (Figure 3) numerically; however, we highlighted the high RoB  
252present in the study for the four domains evaluated.

253       Regarding reproducibility, the long duration tests seem to be more reproducible  
254than the short duration tests, presenting more reliable measurements, ranging from 0.85  
255to 0.94, indicating strong levels of agreement<sup>22</sup>. Factors such as absorbency,  
256evaporation, level of physical activity, and fluid intake may modify their results every 4–6  
257hours, thereby increasing costs <sup>24,31</sup>.

258       The reproducibility of the short-duration pad tests was the least investigated; the  
2591-hour protocol showed stronger reliability (0.96) compared to the 20-min protocol (0.75).  
260The 20-min protocol presented lower standard deviations, indicating better agreement,  
261than the 1h protocol, but with variation coefficients of 157%–326%<sup>36</sup> which can  
262compromise the reliability of measures. The Bland-Altman analysis is not appropriate for  
263comparing repeated measurements, except by adding a random-model effect to the  
264analysis, which was not carried out in the selected studies <sup>42</sup>.

265       We suggest that, both for research and clinical practice, the results of the 1-hour  
266pad test should be interpreted with caution, and repeated measurements should be  
267performed, as recommended by the ICS <sup>43</sup>, especially in cases where the results do not  
268correlate with the UI symptoms as reported by the patient<sup>44</sup>. The wide variation in  
269agreement between repeated measurements affects the reproducibility of the test, as it  
270may cause inaccuracies in classifying incontinence severity, consequently affecting the  
271prognosis and evaluation of therapeutic response<sup>45</sup>. The association of the pad test with

272other evaluation measures (urodynamics, questionnaires) is recommended for a better  
273comprehension of UI and its underlying factors, as well as for the follow-up of its clinical  
274evolution.

275       The main methodological limitations were the absence of sample calculation and  
276poor description of the type of sampling, the number of evaluators, and repeated  
277measures, as well as unclear evaluations and interpretations of the results, leading to a  
278risk of overestimating the measurement and compromising the verification of the  
279measurement error <sup>21</sup>. Regarding the included studies, most did not present the  
280characteristics of the evaluators and subjects, contributing to the unfeasibility of analysing  
281external validity. Most of them did not include measures of statistical uncertainty,  
282providing limited measures and restricting the interpretation of results<sup>46</sup>.

283       To the best of our knowledge, this is the first review that has synthesized the  
284accuracy, reliability, and reproducibility of the pad test and assessed the quality of  
285evidence, as a previous review only sought to verify the concepts and applications of the  
286pad test<sup>47</sup>. We highlight the strong agreement in the selection processes of the studies  
287and the robust methods used to synthesize and more accurately evaluate the available  
288evidence and analyse the data. Urinary incontinence might be transitory or persistent with  
289dynamic changes in the severity scores because it is a symptom of an underlying  
290condition. The pad test could be an accessible tool to detect these changes.

291       The study limitations were as follows: the process of data extraction was made by  
292a single researcher; no primary studies were developed with elderly populations or  
293comparing different ages; the lack of a “gold standard” comparator is also a limitation as

294not all the studies used the urodynamic test. In addition, UI is a dynamic condition, and  
295the urodynamic test also evaluates an inherently variable biological system. The poor  
296methodological description of the primary studies made it impossible to judge some  
297biases on data extraction; and it was not possible to present meta-analysis for  
298summarising sensitivity/specificity values because the studies presented significant  
299methodological bias, different cut-off points between the long-duration protocols, and  
300were insufficient to satisfy the bivariate model for meta-analysis<sup>48</sup>.

301        This review demonstrated that there are significant biases in the methodological  
302conduct of pad test accuracy and reproducibility studies, despite it being a widely  
303disseminated and used clinical tool. Therefore, future research on the accuracy of the  
304pad test should follow the recommendations of the Standards for Reporting of Diagnostic  
305Accuracy Studies guidelines <sup>49</sup>. Reproducibility studies should follow the GRRAS  
306checklist<sup>21</sup> for better designs and measurement safety.

### 307**Conclusion**

308        The evidence regarding the use of the pad test as a more objective evaluation tool  
309for urinary incontinence is divergent, and the studies present a high risk of bias. Thus,  
310they should be interpreted with caution. Among the analysed protocols, the 1-hour pad  
311test showed better accuracy but poorer reproducibility compared to the long-duration  
312tests. The 20-min pad test was found to be the least recommendable because it has less  
313support in the literature and low accuracy.

314 New studies with greater methodological rigor, incorporating man, and in  
315 compliance with international guidelines need to be developed to achieve more reliable  
316 results.

### 317 References

3181. Gibson W, Wagg A. Incontinence in the elderly, “normal” ageing, or unaddressed  
319 pathology? *Nat Rev Urol*. 2017;14(7):440-448. doi:10.1038/nrurol.2017.53
3202. Drake MJ, Doumouchsis SK, Hashim H, Gammie A. Fundamentals of  
321 urodynamic practice, based on International Continence Society good urodynamic  
322 practices recommendations. *Neurourol Urodyn*. 2018;37(S6):S50-S60.  
323 doi:10.1002/nau.23773
3243. Monteiro MV de C, Fonseca AMRM da, Silva Filho AL. Valor do estudo  
325 urodinâmico no tratamento da incontinência urinária. *Femina*. 2012.
3264. Kopp DM, Bengtson AM, Tang JH, Chipungu E, Moyo M, Wilkinson J. Use of a  
327 postoperative pad test to identify continence status in women after obstetric  
328 vesicovaginal fistula repair: a prospective cohort study. *BJOG*. 2017;124(6):966-  
329 972. doi:10.1111/1471-0528.14505
3305. Yi YA, Keith CG, Graziano CE, et al. Strong correlation between standing cough  
331 test and 24-hour pad weights in the evaluation of male stress urinary  
332 incontinence. *Neurourol Urodyn*. 2020;39(1):319-323. doi:10.1002/nau.24200
3336. Abdel-fattah M, Barrington JW, Youssef M. The standard 1-hour pad test: does it  
334 have any value in clinical practice? *Eur Urol*. 2004;46(3):377-380.  
335 [http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15306111&lang](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15306111&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)  
336 [g=pt-br&site=ehost-live&authtype=ip,cookie,uid](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15306111&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid).
3377. James, ED; Flack, FC; Caldwell, KP; Martin M. Continuous measurement of urine  
338 loss and frequency in incontinent patients. Preliminary report. *Br J Urol*.  
339 1971;43(2):233-237.
3408. Sutherst JR, Brown MC, Richmond D. Analysis of the pattern of urine loss in  
341 women with incontinence as measured by weighing perineal pads. *Br J Urol*.  
342 1986;58(3):273-278.  
343 [http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=3719248&lang](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=3719248&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)  
344 [=pt-br&site=ehost-live&authtype=ip,cookie,uid](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=3719248&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid).
3459. Hahn I, Fall M. Objective quantification of stress urinary incontinence: A short,  
346 reproducible, provocative pad-test. *Neurourol Urodyn*. 1991;10(5):475-481.  
347 doi:10.1002/nau.1930100503
34810. Jørgensen L, Lose G, Andersen JT. One-Hour pad-weighing test for objective  
349 assessment of female urinary incontinence. *Obstet Gynecol*. 1987;69(1):39-42.



- 350 doi:10.1016/0020-7292(87)90383-3
35111. Lose G, Jørgensen L, Thunedborg P. 24-hour home pad weighing test versus 1-  
352 hour ward test in the assessment of mild stress incontinence. *Acta Obstet*  
353 *Gynecol Scand.* 1989;68(3):211-215. doi:10.3109/00016348909020991
35412. Jakobseny H, Vedel P, Andersen JT. Objective assessment of urinary  
355 incontinence: An evaluation of three different pad-weighing tests. *Neurourol*  
356 *Urodyn.* 1987;6(4):325-330. doi:10.1002/nau.1930060407
35713. Soto González M, Da Cuña Carrera I, Lantarón Caeiro EM, Gutiérrez Nieto M,  
358 López García S, Ojea Calvo A. Correlation between the 1-hour and 24-hour pad  
359 test in the assessment of male patients with post-prostatectomy urinary  
360 incontinence. *Progrès en Urol.* 2018;28(11):536-541.  
361 doi:https://doi.org/10.1016/j.purol.2018.06.011
36214. Krhut J, Zachoval R, Smith PP, et al. Pad weight testing in the evaluation of  
363 urinary incontinence. *Neurourol Urodyn.* 2014;33(5):507-510.  
364 doi:10.1002/nau.22436
36515. Buehler AM, Ascef B de O, Oliveira Júnior HA de, Ferri CP, Fernandes JG.  
366 Rational use of diagnostic tests for clinical decision making. *Rev Assoc Med Bras.*  
367 2019;65(3):452-459. doi:10.1590/1806-9282.65.3.452
36816. Henderson JW, Kane SM, Mangel JM, et al. A Randomized Comparative Study  
369 Evaluating Various Cough Stress Tests and 24-Hour Pad Test with Urodynamics  
370 in the Diagnosis of Stress Urinary Incontinence. *J Urol.* 2018;199(6):1557-1564.  
371 doi:10.1016/j.juro.2017.11.073
37217. McInnes MDF, Moher D, Thombs BD, et al. Preferred Reporting Items for a  
373 Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies.  
374 *JAMA.* 2018;319(4):388. doi:10.1001/jama.2017.19163
37518. Deeks JJ, Wisniewski S DC. Guide to the contents of a Cochrane Diagnostic Test  
376 Accuracy Protocol. In: *Cochrane Handbook for Systematic Reviews of Diagnostic*  
377 *Test Accuracy Version 1.0.0. The.* ; 2013:3-15.
37819. Jiang YH, Chen SF, Kuo HC. Role of videourodynamic study in precision  
379 diagnosis and treatment for lower urinary tract dysfunction. *Tzu Chi Med J.*  
380 2020;32(2):121-130. doi:10.4103/tcmj.tcmj\_178\_19
38120. Reitsma JB, Leeflang MMG, Sterne JAC, et al. QUADAS-2: A Revised Tool for  
382 the Quality Assessment of Diagnostic Accuracy Studies. *Ann Intern Med.*  
383 2011;155(4):529-536.
38421. Kottner J, Audigé L, Brorson S, et al. Guidelines for reporting reliability and  
385 agreement studies (GRRAS) were proposed. *J Clin Epidemiol.* 2011;64(1):96-  
386 106. doi:10.1016/j.jclinepi.2010.03.002
38722. McHugh ML. Lessons in biostatistics interrater reliability : the kappa statistic.  
388 *Biochem Medica.* 2012;22(3):276-282.

38923. Matharu GS, Assassa RP, Williams KS, et al. Objective Assessment of Urinary  
390 Incontinence in Women: Comparison of the One-Hour and 24-Hour Pad Tests.  
391 *Eur Urol.* 2004;45(2):208-212. doi:<https://doi.org/10.1016/j.eururo.2003.09.006>
39224. Karantanis E, Allen W, Stevermuer TL, Simons AM, O'Sullivan R, Moore KH. The  
393 repeatability of the 24-hour pad test. *Int Urogynecol J Pelvic Floor Dysfunct.*  
394 2005;16(1):63-68.  
395 [http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15647965&lan](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15647965&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)  
396 [g=pt-br&site=ehost-live&authtype=ip,cookie,uid.](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=15647965&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)
39725. Timmermans L, Mélot C, Wespes E, Falez F. Analyse de la valeur du  
398 questionnaire ICIQ-sf et du test d'incontinence sur une heure pour le diagnostic  
399 d'incontinence urinaire objectivé par un bilan urodynamique. *Pelvi-perineologie.*  
400 2011;6(3-4):162-165. doi:10.1007/s11608-011-0373-y
40126. Price DM, Noblett K. Comparison of the cough stress test and 24-h pad test in the  
402 assessment of stress urinary incontinence. *Int Urogynecol J.* 2012;23(4):429-433.  
403 doi:10.1007/s00192-011-1602-1
40427. Versi E, Orrego G, Hardy E, Seddon G, Smith P, Anand D. Evaluation of the  
405 home pad test in the investigation of female urinary incontinence. *BJOG An Int J*  
406 *Obstet Gynaecol.* 1996;103(2):162-167. doi:10.1111/j.1471-0528.1996.tb09669.x
40728. Wu WY, Sheu BC, Lin HH. Comparison of 20-minute pad test versus 1-hour pad  
408 test in women with stress urinary incontinence. *Urology.* 2006;68(4):764-768.  
409 doi:10.1016/j.urology.2006.04.018
41029. Wu W-Y, Sheu B-C, Lin H-H. Twenty-minute pad test: Comparison of infusion of  
411 250ml of water with strong-desire amount in the bladder in women with stress  
412 urinary incontinence. *Eur J Obstet Gynecol Reprod Biol.* 2008;136(1):121-125.  
413 doi:<https://doi.org/10.1016/j.ejogrb.2007.02.030>
41430. MacHold S, Olbert PJ, Hegele A, Kleinhans G, Hofmann R, Schrader AJ.  
415 Comparison of a 20-min pad test with the 1-hour pad test of the international  
416 continence society to evaluate post-prostatectomy incontinence. *Urol Int.*  
417 2009;83(1):27-32. doi:10.1159/000224864
41831. Malik RD, Cohn JA, Fedunok PA, Chung DE, Bales GT. Assessing variability of  
419 the 24-hour pad weight test in men with post-prostatectomy incontinence. *Int Braz*  
420 *J Urol.* 2016;42(2):327-333. doi:10.1590/S1677-5538.IBJU.2014.0506
42132. Klarskov P, Hald T. Reproducibility and reliability of urinary incontinence  
422 assessment with a 60 min test. *Scand J Urol Nephrol.* 1984;18(4):293-298.  
423 doi:10.3109/00365598409180199
42433. Victor A, Larsson G, Åsbrink AS. A simple patient-administered test for objective  
425 quantitation of the symptom of urinary incontinence. *Scand J Urol Nephrol.*  
426 1987;21(4):277-279. doi:10.3109/00365598709180782
42734. Mouritsen L, Berild G, Hertz J. Comparison of different methods for quantification

- 428 of urinary leakage in incontinent women. *Neurourol Urodyn*. 1989;8(6):579-586.  
429 doi:10.1002/nau.1930080604
43035. Versi E, Cardozo L, Anand D, Cooper D. Symptoms analysis for the diagnosis of  
431 genuine stress incontinence. *Br J Obstet Gynaecol*. 1991;98(8):815-819.  
432 doi:10.1111/j.1471-0528.1991.tb13488.x
43336. Siltberg H, Larsson G, Victor A. Reproducibility of a new method to determine  
434 cough-induced leak-point pressure in women with stress urinary incontinence. *Int*  
435 *Urogynecol J Pelvic Floor Dysfunct*. 1996;7(1):13-19.  
436 [http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=8798081&lang](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=8798081&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)  
437 [=pt-br&site=ehost-live&authtype=ip,cookie,uid.](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=8798081&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)
43837. GROUTZ A, BLAIVAS JG, CHAIKIN DC, et al. Noninvasive outcome measures of  
439 urinary incontinence and lower urinary tract symptoms: A Multicenter study of  
440 micturition diary and pad tests. *J Urol*. 2000;164(3 Part 1):698-701.  
441 doi:10.1016/S0022-5347(05)67284-9
44238. Simons AM, Yoong WC, Buckland S, Moore KH. Inadequate repeatability of the  
443 one-hour pad test: the need for a new incontinence outcome measure. *BJOG*.  
444 2001;108(3):315-319.  
445 [http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=11281474&lan](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=11281474&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)  
446 [g=pt-br&site=ehost-live&authtype=ip,cookie,uid.](http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=11281474&lang=pt-br&site=ehost-live&authtype=ip,cookie,uid)
44739. Costantini E, Lazzeri M, Bini V, Giannantoni A, Mearini L, Porena M. Sensitivity  
448 and specificity of one-hour pad test as a predictive value for female urinary  
449 incontinence. *Urol Int*. 2008;81(2):153-159. doi:10.1159/000144053
45040. Bossuyt P, Davenport C, Deeks J, Hyde C, Leeflang M, Scholten R. Chapter 11  
451 Interpreting results and drawing conclusions. In: *Cochrane Handbook for*  
452 *Systematic Reviews of Diagnostic Test Accuracy*. ; 2013:1-31.
45341. Tsui JF, Shah MB, Weinberger JM, et al. Pad count is a poor measure of the  
454 severity of urinary incontinence. *J Urol*. 2013;190(5):1787-1790.  
455 doi:10.1016/j.juro.2013.05.055
45642. Doğan NÖ. Bland-Altman analysis: A paradigm to understand correlation and  
457 agreement. *Turkish J Emerg Med*. 2018;18(4):139-141.  
458 doi:10.1016/j.tjem.2018.09.001
45943. Abrams P, Cardozo L, Wagg A, Wein A. *Epidemiology of Urinary Incontinence*  
460 *(UI) and Other Lower Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse*  
461 *(POP) and Anal Incontinence (AI)*.; 2016.  
462 [https://www.ics.org/publications/ici\\_6/Incontinence\\_6th\\_Edition\\_2017\\_eBook\\_v2.](https://www.ics.org/publications/ici_6/Incontinence_6th_Edition_2017_eBook_v2.pdf)  
463 [pdf.](https://www.ics.org/publications/ici_6/Incontinence_6th_Edition_2017_eBook_v2.pdf)
46444. Soroka D, Drutz HP, Glazener CMA, Hay-Smith EJC, Ross S. Perineal pad test in  
465 evaluating outcome of treatments for female incontinence: a systematic review.  
466 *Int Urogynecol J Pelvic Floor Dysfunct*. 2002;13(3):165-175.  
467 <http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=12140710&lan>

- 468 g=pt-br&site=ehost-live&authtype=ip,cookie,uid.
46945. Hess AS, Hess JR. Understanding standard deviations and standard errors.  
470 *Transfusion*. 2016;56(6):1259-1261. doi:10.1111/trf.13625
47146. O'Brien SF, Yi QL. How do I interpret a confidence interval? *Transfusion*.  
472 2016;56(7):1680-1683. doi:10.1111/trf.13635
47347. Maranhão TM de O, Bernardo-Filho M, Galvão LLLF, Micussi MTABC. Pad-test:  
474 uma revisão sobre conceitos e utilização. *Femina*. 2008:243-246.
47548. Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Chapter 10 Analysing  
476 and Presenting Results. In: *Cochrane Handbook for Systematic Reviews of*  
477 *Diagnostic Test Accuracy*. ; 2013.
47849. Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting  
479 diagnostic accuracy studies: explanation and elaboration. *BMJ*. 2016;6:1-17.  
480 doi:10.1136/bmjopen-2016- 012799
- 481

482Table 1. Extraction of data from studies on PadTest accuracy for 20-min, 1-hour, 24-hour and 48-hour pad tests

Author	Year	Sex (age; range or MD ± SD)	Type of UI	Design	n	Pad test	VP	VN	FP	FN	S (95% CI)	E (95% CI)
Versi et al.	1996	F (absent)	SUI (105), UUI/MUI (44)	Prospective	105**	48 h	57	31	12	5	0.93 (0.84–0.98)	0.84 (0.68–0.94)
Matharu et al.	2004	F (>40) *	SUI (132), UUI (83), MUI (79)	Cross-sectional	341	1 h	205	28	19	89	0.70 (0.64–0.75)	0.60 (0.44–0.74)
						24 h	186	30	17	108	0.63 (0.57–0.69)	0.64 (0.49–0.77)
Karantanis et al.	2005	F (57; 46–68)	SUI (66), MUI (30), UUI (6), others (6)	Cross-sectional	108	24 h	108	0	0	0	1.00 (0.97–1.00)	Not estimable
Price and Noblett	2012	F (56 ± 10)	SUI (53), UUI (2)	Prospective	55	24 h	30	3	2	20	0.60 (0.45–0.74)	0.60 (0.15–0.95)
Wu, Sheu and Lin	2008	F (53.6 ± 2,6)	SUI (64), UUI (1), MUI (18)	Cross-sectional	83	20 min	59	0	24	0	0.71 (0.60–0.81)	Not estimable
Wu, Sheu and Lin	2006	F (53.3 ± 12)	SUI (72), UUI (11), MUI (17)	Cross-sectional	100	20 min	46	0	54	0	0.46 (0.36–0.46)	Not estimable
						1 h	34	0	0	66	0.34 (0.25–0.44)	Not estimable
Costantini et al.	2008	F (69, 20–90)	SUI (43), MUI (45), UUI (16)	Cross-sectional	158	1 h	87	38	16	17	0.84 (0.75–0.90)	0.70 (0.56–0.82)
Timmermans et al.	2011	F/M (58 ± 15)	UUI (42), SUI (39), MUI (25)	Cross-sectional	120	1 h	101	14	0	5	0.95 (0.89–0.98)	1.00 (0.77–1.00)

483MD, mean difference; SD, standard deviation; UI, urinary incontinence; VP: true positive; VN, true negative; FP, false positive; FN, false negative; S, sensitivity; E, specificity, SUI, stress urinary incontinence; UUI, urge urinary incontinence; MUI, mixed urinary incontinence.

485\*Patients over 40 years. \*\*Only cases of SUI were analysed

486

487

488Table 2. Extraction of data from the studies on the reproducibility of the 20-min, 1-hour, 24-hour, and 48-hour pad test.

Author	Year	Sex (Age, range; or MD ± SD)	Type of UI	n	pad test	Reproducibility (95% CI)	Interval (days)	Statistical measure
Klarskov and Hald	1984	F/M (52, 17–75)	SUI, UUI, MUI	19	1 h	0.96	1–36	Correlation coefficient
Victor et al.	1987	F (50, 21–73)	Not Informed	15	24 h 48 h	0.66 0.90	6–28	ICC
Mouritsen et al.	1989	F (55, 40–61)	SUI (39), MUI (33)	54	24 h	0.87	**	Pearson Correlation
Lose et al.	1989	F (57, 20–79)	SUI (23), MUI (8)	31	24 h	0.82	0	Correlation
Hahn and Fall	1991	F (52, 30–79)	SUI	50	20 min	0.94	7	Pearson Correlation
Versi et al.	1996	F (absent)	SUI (62), UUI/MUI (44)	112	24 h 48 h	0.90 (0.87–0.94) 0.94 (0.93–0.95)	7	Pearson Correlation
Siltberg et al.	1996	F (49, 37–64)	SUI	21	20 min	0.75 -0.3 (±19.9)*	21	Correlation/ Bland-Altman method
Groutz et al.	2000	F/M (64, 22–84)	UUI (34%), SUI (22%), MUI (26%), OA (16%)	92 F/ 17 M	24 h 48 h	0.72 0.87	7	CCC
Simons et al.	2001	F (56, 44–66)	Not Informed	56	1 h	9.7 (± 29.7) *	3–10	Bland-Altman method
Karantanis et al.	2005	F (57, 48–68)	SUI(66), MUI (30), UUI (6), others (6)	104	24 h	0.88	0	Pearson Correlation
Machold et al.	2009	M (66, 53–80)	PPUI	20	20 min	0.76	7–14	Spearman correlation coefficient
Malik et al.	2016	M (64.5 ± 8.1)	PPUI	25	24 h	0.85 (0.73–0.93)	2	ICC

489MD, mean difference; SD, standard deviation; UI, urinary incontinence; SUI, stress urinary incontinence; UUI, urge urinary incontinence; MUI, mixed urinary incontinence; ICC, intraclass correlation coefficient; CCC, Lin's concordance correlation coefficient. OA, overactive bladder; PPUI, Post-prostatectomy urinary incontinence . \*Mean difference (± SD), \*\*not reported

492Table 3. Analysis of the methodological quality of the PadTest reproducibility studies included in the review, based on the Guideline for  
493Reporting Reliability and Agreement Studies (GRRAS).

	<b>Assessed Item (GRAAS)</b>	<b>Klarskov e Hald (1984)</b>	<b>Victor et al. (1987)</b>	<b>Mouritsen et al. (1989)</b>	<b>Lose et al. (1989)</b>	<b>Hahn e Fall (1991)</b>	<b>Versi et al. (1996)</b>	<b>Siltberg et al. (1996)</b>	<b>Groutz et al. (2000)</b>	<b>Simons et al. (2001)</b>	<b>Karantanis et al. (2005)</b>	<b>Mach old et al. (2009)</b>	<b>Malik et al. (2016)</b>
<b>Title and abstract</b>	Identify in title or abstract that interrater/intrarater reliability or agreement was investigated	Y	Y	N	N	Y	Y	N	Y	Y	Y	Y	N
<b>Introduction</b>	Name and describe the diagnostic or measurement device of interest explicitly.	Y	N	Y	Y	N	Y	N	N	Y	Y	Y	Y
	Specify the subject population of interest	Y	Y	N	N	N	Y	Y	N	N	Y	Y	Y
	Specify the rater population of interest	N	N	N	N	N	N	N	Y	Y	Y	Y	N
<b>Methods</b>	Describe what is already known about reliability and agreement and provide a rationale for the study	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	N	N
	Explain how the sample size was chosen. State the determined number of raters, subjects/objects, and replicate observations	N	Y	N	N	N	U	U	U	Y	U	N	Y
	Describe the sampling method	N	N	N	N	N	N	N	Y	Y	Y	N	Y
	Describe the measurement/rating process	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y
	State whether measurements/ratings were conducted independently	N	N	U	U	U	U	U	U	U	U	N	U
	Describe the statistical analysis	N	N	Y	N	Y	U	Y	Y	N	Y	Y	Y
	State the actual number of raters and subjects/objects which were included and the number of replicate observations which were conducted.	Y	Y	N	N	N	Y	Y	U	N	Y	U	U
<b>Results</b>	Describe the sample characteristics of raters and subjects (e.g. training, experience)	N	N	N	N	N	N	N	N	N	N	N	N
	Report estimates of reliability and agreement including measures of statistical uncertainty.	N	N	N	N	N	Y	Y	N	Y	N	N	Y

Discussion	Discuss the practical relevance of results	N	N	N	N	N	Y	N	Y	Y	Y	Y	Y
Auxiliary	Provide detailed results if possible	N	N	N	N	N	N	N	N	N	N	N	N
Score (%)		<b>6/15 (40)</b>	<b>5/15 (33)</b>	<b>4/15 (27)</b>	<b>3/15 (33)</b>	<b>4/15 (27)</b>	<b>8/15 (53)</b>	<b>8/15 (53)</b>	<b>7/15 (47)</b>	<b>9/15 (60)</b>	<b>9/15 (60)</b>	<b>7/15 (47)</b>	<b>8/15 (53)</b>

494N:No, Y:Yes, U: Unclear



495 **Figure 1. Flow diagram pad test accuracy**

496 **Figure 2. Risk of bias and applicability concerns summary and graph: Review**  
497 **authors judgments about each domain presented as percentages across included**  
498 **studies**

499 **Figure 3. Coupled forest plot from studies of PadTest accuracy compared to**  
500 **urodynamic test.**

501